Supplement Scholar
Metabolic / Incretin

Survodutide

Research compound. This is not a dietary supplement. Unless it is identified as an approved prescription drug, it is not approved by the FDA for human use. This page summarizes published research for education only; we do not sell it or link to sellers.

Survodutide. Dual GLP-1 / glucagon receptor agonist studied for obesity and MASH.

How it works. Combines GLP-1-mediated appetite and glycemic control with glucagon-mediated energy expenditure and hepatic fat mobilization.

What the research supports. 2 graded claims. Strongest: Targets both weight and liver fat (preclinical).

Hormonal impact. Effects on GLP-1 signaling, Glucagon signaling, Hepatic triglyceride content.

Side effects and interactions. 1 medication interaction listed. Serious: Pancreatitis and gallbladder events under monitoring.

Stacking. Pairs well with Structured lifestyle intervention. Avoid combining with MEN-2 syndrome.

Common forms. Available as Subcutaneous injection.

Community. Experiences from people who have tried Survodutide. Anecdotes are not medical advice.

Survodutide. Dual GLP-1 / glucagon receptor agonist studied for obesity and MASH.

No single structure

What it is

Survodutide is a once-weekly dual agonist of GLP-1 and glucagon receptors developed for obesity and metabolic-dysfunction-associated steatohepatitis (MASH).

Also called

BI 456906

How it works

Combines GLP-1-mediated appetite and glycemic control with glucagon-mediated energy expenditure and hepatic fat mobilization.

Pathways

  • GLP-1 receptor
  • Glucagon receptor
  • Hepatic lipid oxidation

Effects

  • ↓Body weight decreases
  • ↓Hepatic steatosis in MASH decreases

What the research supports

Targets both weight and liver fatpreclinical
Dual mechanismpreclinical

Strong: consistent results across large trials or meta-analyses. Moderate: several trials, mostly positive. Limited: small or mixed studies. Preclinical: animal or cell research only.

Hormonal impact

↑GLP-1 signalingincreases
↑Glucagon signalingincreases
↓Hepatic triglyceride contentdecreases

Side effects & interactions

Common side effects

  • Nausea
  • Vomiting
  • Diarrhea

Serious

  • Pancreatitis and gallbladder events under monitoring

Medication interactions

Insulin or sulfonylureasmoderate

Hypoglycemia risk requires dose adjustment.

Check any supplement–medication combination with your pharmacist before starting.

Combines with

Pairs well

  • Structured lifestyle interventionMaximizes durable weight and metabolic response.

Avoid combining

  • MEN-2 syndromeClass-level caution with incretin therapies.

Common forms

  • Subcutaneous injection

Discussion

Loading discussion…